Affinity Maturation or Degeneration for Custom Antibody

Monoclonal antibodies have been approved to treat a variety of diseases. The binding characteristics of these therapeutic antibodies can be altered by maturation (gain of affinity) or degeneration (loss of affinity) techniques to confer different functionalities that will be useful to new areas of research and therapeutics. For example, a bispecific antibody would benefit from such an alteration to reduce its binding affinities to each single antigen, thereby acquiring an increased binding specificity to cells carrying both antigens.

BiCell Scientific’s affinity maturation or degeneration service utilizes a unique and proprietary yeast 2-hybrid platform to screen mutations in the the complementarity-determining regions (CDRs) within the F_v domain of both heavy chain and light chain of the antibody molecule, in order to experimentally alter the binding affinities of custom-made or existing therapeutic monoclonal antibodies to suit a wide range of new applications.